Seres Therapeutics Inc (MCRB)

$0.9166

+0.01

(+0.96%)

Market is closed - opens 7 PM, 28 May 2024

Insights on Seres Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 126.47M → 64.0K (in $), with an average decrease of 89.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -47.85M → -40.13M (in $), with an average increase of 9.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 67.0% return, outperforming this stock by 147.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 238.7% return, outperforming this stock by 334.4%

Performance

  • $0.90
    $0.93
    $0.92
    downward going graph

    2.17%

    Downside

    Day's Volatility :3.12%

    Upside

    0.97%

    downward going graph
  • $0.54
    $6.26
    $0.92
    downward going graph

    41.3%

    Downside

    52 Weeks Volatility :91.37%

    Upside

    85.3%

    downward going graph

Returns

PeriodSeres Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-14.34%
-1.8%
0.0%
6 Months
-20.98%
10.1%
0.0%
1 Year
-80.62%
13.2%
0.0%
3 Years
-95.73%
17.0%
-21.4%

Highlights

Market Capitalization
137.5M
Book Value
- $0.39
Earnings Per Share (EPS)
-0.59
PEG Ratio
-0.11
Wall Street Target Price
6.2
Profit Margin
-65.18%
Operating Margin TTM
-60.7%
Return On Assets TTM
-15.74%
Return On Equity TTM
-538.57%
Revenue TTM
126.8M
Revenue Per Share TTM
0.95
Quarterly Revenue Growth YOY
-93.4%
Gross Profit TTM
-165.8M
EBITDA
-70.6M
Diluted Eps TTM
-0.59
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.03
EPS Estimate Next Year
-0.77
EPS Estimate Current Quarter
-0.34
EPS Estimate Next Quarter
-0.31

Analyst Recommendation

Buy
    76%Buy
    15%Hold
    7%Sell
Based on 13 Wall street analysts offering stock ratings for Seres Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
2
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 576.41%

Current $0.92
Target $6.20

Technicals Summary

Sell

Neutral

Buy

Seres Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Seres Therapeutics Inc
Seres Therapeutics Inc
11.1%
-20.98%
-80.62%
-95.73%
-76.07%
Moderna, Inc.
Moderna, Inc.
54.31%
114.37%
31.98%
-5.11%
673.49%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
11.53%
23.42%
35.86%
98.13%
219.88%
Novo Nordisk A/s
Novo Nordisk A/s
7.24%
30.97%
66.95%
238.66%
467.54%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
14.96%
30.49%
38.47%
120.96%
164.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Seres Therapeutics Inc
Seres Therapeutics Inc
NA
NA
-0.11
-1.03
-5.39
-0.16
NA
-0.39
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.6
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.99
28.99
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.75
46.75
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.23
29.23
0.53
17.14
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Seres Therapeutics Inc
Seres Therapeutics Inc
Buy
$137.5M
-76.07%
NA
-65.18%
Moderna, Inc.
Moderna, Inc.
Buy
$63.9B
673.49%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
219.88%
28.99
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$605.7B
467.54%
46.75
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.3B
164.5%
29.23
39.46%

Institutional Holdings

  • Flagship Ventures Management, Inc.

    15.26%
  • FMR Inc

    12.80%
  • BlackRock Inc

    4.85%
  • Vanguard Group Inc

    4.45%
  • Hudson Bay Capital Management LP

    2.85%
  • Bank of America Corp

    1.56%

Company Information

seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.

Organization
Seres Therapeutics Inc
Employees
233
CEO
Mr. Eric D. Shaff M.B.A.
Industry
Health Technology

FAQs